Furthermore, Dong Y et al. found that high expression of CDKN2A can not only contribute to a poor survival outcome of patients with CRC, but also may guide PD-1 mediated immunotherapy for patients with CRC 43. This evidence concerns the gene CDKN2A and colorectal carcinoma.